Understanding DCTs: Decentralized Clinical Trials
Curebase & CISCRP Present a Flash Webinar
15-MINUTE FLASH WEBINAR
DCTs: Decentralized Clinical Trials
Wednesday, August 18th at 12PM EST
Panelists will provide information for patients, patient advocates & the public about what decentralized clinical trials are, how they work, and the importance of diversity in clinical research participation.
Adam Samson, Moderator
Sr. Director of Clinical Operations & Customer Success
For over a decade, Adam has conducted clinical trials across multiple therapeutic areas as a research coordinator, monitor, project manager, and director at various types of organizations—investigational sites, CROs, academia, pharma, and tech. He received a master's in clinical research from The George Washington University. In June 2020, he joined as Director of Clinical Operations at Curebase, a provider of software and services purpose-built for decentralized clinical trials (DCTs), where he is responsible for oversight of DCT services.
Arsheen Ali, Panelist
Clinical Project Manager
Arsheen Ali is a Project Manager and has served in this role with Curebase for over two years. In this capacity, she manages multiple decentralized clinical trials. Her background includes a variety of healthcare and research experience. She received her bachelor’s in integrative biology from UC Berkeley. Arsheen’s main interests are public health (population and community health focus), increasing healthcare quality and access (especially for minority/marginalized populations), and maximizing the efficiency of research.
Lead Virtual Research Coordinator
Myra Lane is Lead Virtual Research Coordinator at Curebase with over three years of clinical research experience in the decentralized clinical trial space interacting directly with patients. She has worked in various therapeutic areas including neurology, dermatology, and oncology. She is passionate about the impact that the digital therapeutics approach has on addressing unmet patient needs by providing universal access to clinical research and accelerating the development of treatments.